This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

ACD-856

Extensively Studied

First-in-class small-molecule positive allosteric modulator of all three Trk receptors (TrkA/TrkB/TrkC) — the receptors that BDNF, NGF,…

Aliases (3)

ACD856 · NeuroRestore ACD856 · AlzeCure ACD-856

TYPICAL DOSE

1–150 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

No defensible recommendation — there is no clin…

As prescribed

STORAGE

store (Sweden)** | Not for sale | N/A | Not com…

Room temp

Overview

What is ACD-856?

ACD-856 is an investigational small-molecule positive allosteric modulator of the TrkA, TrkB, and TrkC neurotrophin receptors developed by AlzeCure. It is in clinical development for Alzheimer's disease and other cognitive disorders, with the goal of restoring neurotrophin signaling without direct receptor agonism.

Key Benefits

Potentiates endogenous NGF and BDNF signaling, supports cognitive function and synaptic plasticity, has demonstrated cognition-enhancing effects in preclinical models, and offers a safer profile than direct TrkB agonists.

Mechanism of Action

Positive allosteric modulator of pan-Trk receptors (TrkA/B/C). Amplifies the endogenous response to neurotrophins (NGF, BDNF, NT-3) without direct receptor activation, enhancing downstream PI3K/Akt and MAPK signaling only where neurotrophins are present.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options3 known

ACD856NeuroRestore ACD856AlzeCure ACD-856

StatusNot scheduled (investigational only); not approved in any jurisdiction; gray-market research-chemical only

Peptide Interactions

cerebrolysin

Synergistic

Cerebrolysin acts upstream by *mimicking* BDNF/NGF at the extracellular Trk binding site (the drug supplies the ligand). ACD-856 acts downstream by *amplifyi…

semax / NASA (n-acetyl-semax-amidate)

Synergistic

Both are reported to upregulate BDNF mRNA / protein. ACD-856 would amplify whatever BDNF the semax bumps up.

bpc-157

Synergistic

BPC-157 has been reported (rodent data) to upregulate BDNF expression, particularly in injury contexts. Stack would be: BPC raises BDNF, ACD-856 makes the BD…

dihexa

Synergistic

Dihexa's mechanism is HGF/c-Met activation → indirect BDNF release / Trk pathway involvement. Stacking dihexa + ACD-856 stacks two different upstream feeders…

af710b (Anavex 3-71)

Synergistic

M1 muscarinic + sigma-1 mechanism, distinct neuroprotective pathway. Theoretically complementary (different receptor systems), no overlap risk.

TAK-653

Synergistic

AMPA-receptor PAM, glutamate-side. Hits a different but parallel plasticity pathway. Complementary in theory, both are unproven in humans.

NGF antibody therapies (tanezumab, fasinumab)

Avoid

ACD-856 amplifies the very signaling these drugs block. (Irrelevant for users in this archetype but flag for completeness.)

High-dose acute TrkB agonists

Avoid

(7,8-DHF in superphysiological doses, dihexa at high dose) — theoretical risk of compounded over-signaling in regions with already-high BDNF tone. Mechanism …

Other compounds with seizure-lowering risk

Avoid

until extended human safety is in, treat ACD-856 as a possible threshold-lowerer.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Day 1
PK-driven acute peak per administration. Verify dose tolerated.
Week 1
Steady-state reached for most daily-dosed pharma.
Week 2-4
Therapeutic effect established; titration window if needed.
Long-term
Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety

Common in Phase 1 (healthy volunteers):
- Headache (mild, most common)
- Nausea (mild)
Less common (Phase 1 MAD):
- Transient lipase + amylase elevation (2/24 subjects, normalized without intervention) — flag for pancreatic monitoring in any human use
Rare-serious:
- None reported in n≈80 healthy human exposures across SAD + MAD + Phase 1b.
Theoretical (mechanism-based, not yet observed in humans):
- Pain potentiation — TrkA is the NGF receptor, and NGF signaling drives nociceptor sensitization. NGF-blocking antibodies (tanezumab) reduce pain. A Trk-PAM theoretically amplifies NGF signaling and could increase pain sensitivity. This has not been reported in Phase 1 but is the most plausible mechanism-derived risk and worth flagging.
- TrkB-mediated seizures — chronic TrkB activation drives epileptogenesis in animal models. ACD-856's PAM mechanism (signal amplification only when ligand is present) should be safer than tonic agonism, but seizure risk has not been ruled out in extended exposure.
- Tumor-relevant signaling — Trk receptors drive proliferation in some tumors (Trk-fusion cancers). Trk-PAM activity is unlikely to initiate tumorigenesis (it requires existing neurotrophin gradients), but anyone with a Trk-fusion-positive cancer would be a contraindication category.
Specific watch periods: Unknown — too early to define. Phase 2a will set the first surveillance protocols.